Search

Your search keyword '"Netchiporouk, Elena"' showing total 557 results
Start Over Author "Netchiporouk, Elena"
557 results on '"Netchiporouk, Elena"'

13. Prevalence of omalizumab-resistant chronic urticaria and real-world effectiveness of dupilumab in patients with omalizumab-refractory chronic urticaria: a single-centre experience.

Author

Zhu, Catherine, BinJadeed, Hessah, Gabrielli, Sofianne, Prosty, Connor, Rahme, Elham, Shand, Greg, Fein, Michael, Ben-Shoshan, Moshe, and Netchiporouk, Elena

Subjects
DUPILUMAB, ODDS ratio, CYCLOSPORINE, STANDARD deviations, URTICARIA
Abstract

Chronic urticaria (CU) is characterized by weals (hives) angio-oedema (or both) that last for ≥ 6 weeks, with chronic spontaneous urticaria (CSU) being the most common subtype. Patients with omalizumab-refractory CSU represent an unmet clinical need. In this study, we aimed to assess the prevalence and predictors of omalizumab failure in a large cohort of patients with CU and assess the effectiveness of dupilumab for omalizumab-refractory CU. Of 338 patients with CU, 33 received omalizumab; 69.7% (n = 23) were responders and 30.3% (n = 10) were nonresponders. Bivariate regression demonstrated that female sex [adjusted odds ratio (aOR) 1.53, 95% confidence interval (CI) 1.14–2.06], higher baseline weekly urticaria activity score (aOR 1.05, 95% CI 1.01–1.09) and older age (controlling for sex) (aOR 1.00, 95% CI 1.00–1.01) were associated with omalizumab failure. Of 10 patients with omalizumab-refractory CU, 3 were well controlled with ciclosporin (all children), whereas the 7 adults failed a mean [standard deviation (SD)] of 5.6 (2.6) treatments, including ciclosporin. All seven achieved a complete response with dupilumab, with time to response varying between 1 and 6 months. While our results suggest a favourable efficacy of dupilumab in patients with omalizumab-refractory CU, future confirmatory studies are required. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. Global Approach for Severe Cutaneous Adverse Reactions (GRASS) Survey

Author

Copaescu, Ana Maria, primary, Vogrin, Sara, additional, Khoudja, Rabea Youcef, additional, Netchiporouk, Elena, additional, Kern, Johannes, additional, Goh, Michelle, additional, Ben-Shoshan, Moshe, additional, Holmes, Natasha, additional, Peter, Jonathan, additional, Phillips, Elizabeth, additional, and Trubiano, Jason, additional

Published
2024
Full Text
View/download PDF

16. Montreal Derm FilEZ: Validation of an Online Dermatology Educational Platform for Medical Dermatology Residents, a Randomized Control Trial

Author

Moussa, Sarah, primary, Oliel, Sarah, additional, Ouchene, Lydia, additional, Ridha, Zainab, additional, Powell, Mathieu, additional, Alhalees, Zeinah, additional, Iannattone, Lisa, additional, Gomez-Garibello, Carlos, additional, Besner Morin, Catherine, additional, Mathieu, Steve, additional, Veilleux, Mylène, additional, and Netchiporouk, Elena, additional

Published
2024
Full Text
View/download PDF

22. COVID-19 Immunologic Antiviral Therapy With Omalizumab (CIAO)—a Randomized Controlled Clinical Trial.

Author

Le, Michelle, Khoury, Lauren, Lu, Yang, Prosty, Connor, Cormier, Maxime, Cheng, Mathew P, Fowler, Robert, Murthy, Srinivas, Tsang, Jennifer L Y, Ben-Shoshan, Moshe, Rahme, Elham, Golchi, Shirin, Dendukuri, Nandini, Lee, Todd C, and Netchiporouk, Elena

Subjects
URTICARIA, CLINICAL trials, RANDOMIZED controlled trials, OMALIZUMAB, COVID-19, CORONAVIRUS diseases
Abstract

Background Omalizumab is an anti-immunoglobulin E monoclonal antibody used to treat moderate to severe chronic idiopathic urticaria, asthma, and nasal polyps. Recent research suggested that omalizumab may enhance the innate antiviral response and have anti-inflammatory properties. Objective We aimed to investigate the efficacy and safety of omalizumab in adults hospitalized for coronavirus disease 2019 (COVID-19) pneumonia. Methods This was a phase II randomized, double blind, placebo-controlled trial comparing omalizumab with placebo (in addition to standard of care) in hospitalized patients with COVID-19. The primary endpoint was the composite of mechanical ventilation and/or death at day 14. Secondary endpoints included all-cause mortality at day 28, time to clinical improvement, and duration of hospitalization. Results Of 41 patients recruited, 40 were randomized (20 received the study drug and 20 placebo). The median age of the patients was 74 years and 55.0% were male. Omalizumab was associated with a 92.6% posterior probability of a reduction in mechanical ventilation and death on day 14 with an adjusted odds ratio of 0.11 (95% credible interval 0.002-2.05). Omalizumab was also associated with a 75.9% posterior probability of reduced all-cause mortality on day 28 with an adjusted odds ratio of 0.49 (95% credible interval, 0.06-3.90). No statistically significant differences were found for the time to clinical improvement and duration of hospitalization. Numerically fewer adverse events were reported in the omalizumab group and there were no drug-related serious adverse events. Conclusions These results suggest that omalizumab could prove protective against death and mechanical ventilation in hospitalized patients with COVID-19. This study could also support the development of a phase III trial program investigating the antiviral and anti-inflammatory effect of omalizumab for severe respiratory viral illnesses requiring hospital admission. ClinicalTrials.gov ID: NCT04720612 [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

24. Morphea, Eosinophilic Fasciitis and Cancer: A Scoping Review

Author

Joly-Chevrier, Maxine, primary, Gélinas, Alexa, additional, Ghazal, Stephanie, additional, Moussa, Sarah, additional, McCuaig, Catherine C., additional, Piram, Maryam, additional, Mereniuk, Alexandra, additional, Litvinov, Ivan V., additional, Osman, Mohammed, additional, Pehr, Kevin, additional, and Netchiporouk, Elena, additional

Published
2023
Full Text
View/download PDF

28. Organic solvent exposure and systemic sclerosis: A retrospective cohort study based on the Canadian Scleroderma Research Group registry

Author

Baron, M., Hudson, M., Gyger, G., Pope, J., Larche, M., Khalidi, N., Masetto, A., Sutton, E., Rodriguez Reyna, T.S., Maltez, N., Thorne, C., Fortin, P.R., Ikic, A., Robinson, D., Jones, N., LeClercq, S., Docherty, P., Smith, D., Fritzler, M.J., Kaminska, E., Muntyanu, Anastasiya, Milan, Raymond, Rahme, Elham, Baron, Murray, and Netchiporouk, Elena

Published
2024
Full Text
View/download PDF

29. Assessing Skin Cancer Risk Factors, Sun Safety Behaviors and Melanoma Concern in Atlantic Canada: A Comprehensive Survey Study

Author

Lagacé, François, primary, Noorah, Bibi Nuzha, additional, Conte, Santina, additional, Mija, Lorena Alexandra, additional, Chang, Jasmine, additional, Cattelan, Leila, additional, LeBeau, Jonathan, additional, Claveau, Joël, additional, Turchin, Irina, additional, Gulliver, Wayne, additional, Gniadecki, Robert, additional, Netchiporouk, Elena, additional, Miller Jr., Wilson H., additional, Salopek, Thomas G., additional, Rahme, Elham, additional, Peláez, Sandra, additional, and Litvinov, Ivan V., additional

Published
2023
Full Text
View/download PDF

31. Organic Solvent Exposure and Systemic Sclerosis: A Retrospective Cohort Study Based on the Canadian Scleroderma Research Group Registry

Author

Muntyanu, Anastasiya, primary, Milan, Raymond, additional, Rahme, Elham, additional, Baron, Murray, additional, Netchiporouk, Elena, additional, Baron, M., additional, Hudson, M., additional, Gyger, G., additional, Pope, J., additional, Larche, M., additional, Khalidi, N., additional, Masetto, A., additional, Sutton, E., additional, Reyna, T.S. Rodriguez, additional, Maltez, N., additional, Thorne, C., additional, Fortin, P.R., additional, Ikic, A., additional, Robinson, D., additional, Jones, N., additional, LeClercq, S., additional, Docherty, P., additional, Smith, D., additional, and Fritzler, M.J., additional

Published
2023
Full Text
View/download PDF

32. Skin disorders and interstitial lung disease: Part II—The spectrum of cutaneous diseases with lung disease association

Author

Ouchene, Lydia, primary, Muntyanu, Anastasiya, additional, Assayag, Deborah, additional, Veilleux, Èvicka, additional, Abril, Andy, additional, Ferrara, Giovanni, additional, Yacyshyn, Elaine, additional, Pineau, Christian A., additional, O'Brien, Elizabeth, additional, Baron, Murray, additional, Osman, Mohammed, additional, Gniadecki, Robert, additional, and Netchiporouk, Elena, additional

Published
2023
Full Text
View/download PDF

40. The burden of alopecia areata: A scoping review focusing on quality of life, mental health and work productivity.

Author

Muntyanu, Anastasiya, Gabrielli, Sofianne, Donovan, Jeffrey, Gooderham, Melinda, Guenther, Lyn, Hanna, Sameh, Lynde, Charles, Prajapati, Vimal H., Wiseman, Marni, and Netchiporouk, Elena

Subjects
QUALITY of life, LABOR productivity, MENTAL work, MENTAL health, PHYSICIAN services utilization, COMPULSIVE hair pulling, ALOPECIA areata
Abstract

Alopecia areata (AA) is a common inflammatory autoimmune disease of the hair which can have a significant negative impact on quality of life (QoL), mental health and productivity. The aim of this scoping review is to elucidate the burden of AA focusing on these three realms. Inclusion criteria included all original manuscripts with no restriction on study type or statistical method written in English (or having an English abstract). For QoL 40 articles were included, 85 for psychiatric comorbidities, and 9 for work/school absenteeism/presenteeism mostly consisting of cross‐sectional and observational cohort studies. QoL impairment was detected in over 75% of patients and up to one‐third reported extremely severe QoL impairments. Specific QoL dimensions with the greatest impact were embarrassment, social functioning, as well as shopping and/or housework. Cross‐sectional studies assessing the psychological burden of adult patients with AA found that the presence of signs of anxiety and/or depression ranged from 30% to 68% and affected all age groups. Rates of work absenteeism and unemployment were significantly higher in AA patients compared to healthy controls. Up to 62% reported making major life decisions including relationships, education and career based on their AA. Additionally, the extensive camouflage techniques and time lost from work led to a strong financial burden for patients and the numerous physician visits added to the healthcare costs. The overall impact of AA stretches much further than simply being an aesthetic concern and can negatively impact every part of an individual's life. An individualized approach and effective treatments will help reduce the psychosocial consequences and distress and return patients to their normal state of health. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

43. Safety of COVID-19 mRNA vaccination in children with chronic urticaria

Author

Zhu, Catherine K., primary, Nguyen, Alex, additional, Prosty, Connor, additional, Gabrielli, Sofianne, additional, Laboccetta, Vera, additional, Shand, Greg, additional, Mulé, Pasquale, additional, Netchiporouk, Elena, additional, Le, Michelle, additional, Zhang, Xun, additional, Ke, Danbing, additional, Baum, Sharon, additional, Hakroush, Reman, additional, Greenberger, Shoshana, additional, and Ben-Shoshan, Moshe, additional

Published
2023
Full Text
View/download PDF

45. Measuring h-index and scholarly productivity in academic dermatology in Canada

Author

Azar, Marleine, primary, Lagacé, Francois, additional, Muntyanu, Anastasiya, additional, Netchiporouk, Elena, additional, Zhou, Youwen, additional, Lynde, Charles, additional, Moreau, Linda, additional, Mathieu, Steve, additional, Sasseville, Denis, additional, Asiniwasis, Rachel, additional, Shear, Neil H., additional, Gniadecki, Robert, additional, Rahme, Elham, additional, and Litvinov, Ivan V., additional

Published
2022
Full Text
View/download PDF

46. Geographical distribution of systemic sclerosis in Canada: An ecologic study based on the Canadian Scleroderma Research Group

Author

Muntyanu, Anastasiya, primary, Ouchene, Lydia, additional, Zhou, Siriu, additional, Hudson, Marie, additional, Rezaeian, Mohsen, additional, LaChance, Avery, additional, Litvinov, Ivan V., additional, Baron, Murray, additional, Netchiporouk, Elena, additional, Baron, M., additional, Hudson, M., additional, Gyger, G., additional, Pope, J., additional, Larche, M., additional, Khalidi, N., additional, Masetto, A., additional, Sutton, E., additional, Rodriguez-Reyna, T.S., additional, Maltez, N., additional, Thorne, C., additional, Fortin, P.R., additional, Ikic, A., additional, Robinson, D., additional, Jones, N., additional, LeClercq, S., additional, Docherty, P., additional, Smith, D., additional, and Fritzler, M., additional

Published
2022
Full Text
View/download PDF

47. Supplementary material - Supplemental material for The Role of Sex and Gender in Dermatology - From Pathogenesis to Clinical Implications

Author

Lagacé, François, D’Aguanno, Kathleen, Prosty, Connor, Laverde-Saad, Alexandra, Cattelan, Leila, Ouchene, Lydia, Oliel, Sarah, Genest, Genevieve, Doiron, Philip, Richer, Vincent, Jfri, Abdulhadi, O’Brien, Elizabeth, Lefrançois, Philippe, Powell, Mathieu, Moreau, Linda, Litvinov, Ivan V., Muntyanu, Anastasiya, and Netchiporouk, Elena

Subjects
Medicine
Abstract

Supplemental material, Supplementary material, for The Role of Sex and Gender in Dermatology - From Pathogenesis to Clinical Implications by François Lagacé, Kathleen D’Aguanno, Connor Prosty, Alexandra Laverde-Saad, Leila Cattelan, Lydia Ouchene, Sarah Oliel, Genevieve Genest, Philip Doiron, Vincent Richer, Abdulhadi Jfri, Elizabeth O’Brien, Philippe Lefrançois, Mathieu Powell, Linda Moreau, Ivan V. Litvinov, Anastasiya Muntyanu and Elena Netchiporouk in Journal of Cutaneous Medicine and Surgery

Published
2023
Full Text
View/download PDF

49. Utilization of the Psoriasis Epidemiology Screening Tool (PEST): A Risk Stratification Strategy for Early Referral of Psoriatic Arthritis Patients to Minimize Irreversible Erosive Joint Damage

Author

Chang, Jasmine, primary, Litvinov, Ivan V., additional, Ly, Christina, additional, Netchiporouk, Elena, additional, Tsoukas, Alexander, additional, Thuraisingam, Thusanth, additional, Starr, Michael, additional, Powell, Mathieu, additional, Christodoulou, George, additional, and Shamout, Yassein, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results